TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18030007
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using docetaxel before prostatectomy
Study: 11675332
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m² on days 1-5)
Study: 11675332
Drug: Cyclophosphamide, doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, doxorubicin, and prednisone (CAP; 750 mg/m² cyclophosphamide and 25 mg/m² doxorubicin on day 1 and 40 mg/m² prednisone on days 1-5)
Study: 9629509
Drug: High-dose pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pancreatic enzyme treatment (Panzytrat, 20,000 units of lipase, 18,000 units of amylase, and 1000 units of protease per capsule, 18 capsules daily for 4 weeks)
Study: 9629509
Drug: High-dose pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pancreatic enzyme treatment
Study: 7931188
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment (n = 11)
Study: 3364761
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with epinephrine (5 micrograms/ml)
Study: 3364761
Drug: 0.375% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% bupivacaine with epinephrine (5 micrograms/ml)
Study: 2265168
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with epinephrine (5 micrograms/ml)
Study: 29452204
Drug: Interferon‐α (IFN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐α (IFN) monotherapy or combination therapy of IFN and lamivudine (LAM)
Study: 27105868
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg resveratrol
Study: 31891746
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg resveratrol
Study: 24587636
Drug: Recombinant streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant streptokinase (rSK) 200000 IU, administered rectally every 6 hours for 48 hours.
Study: 24587636
Drug: Phenylephrine-based suppositories
Normalized name: phenylephrine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine-based suppositories (0.25%), administered rectally up to a maximum of 5 days (20 suppositories).
Study: 24587636
Drug: Phenylephrine-based suppositories
Normalized name: phenylephrine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine-based suppositories (0.25%)
Study: 17135753
Drug: Oral cefatrizine
Normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefatrizine (3 doses of 1 g every 12 hours)
Study: 10437748
Drug: Docetaxel (Taxotere)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (Taxotere) 100 mg/m2 every 3 weeks in neoadjuvant chemotherapy
Study: 10437748
Drug: Cisplatin-based induction
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based induction chemotherapy
Study: 8560051
Drug: lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: lysine acetylsalicylate (1800 mg)
Study: 8560051
Drug: ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac (30 mg)
Study: 8560051
Drug: diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (75 mg)
Study: 19740550
Drug: Standard Rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Rehabilitation Treatment (SRT) + Computer‐aided Cognitive Remediation Treatment (CRT)
Study: 19740550
Drug: Standard Rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Rehabilitation Treatment (SRT) + Placebo Training
Study: 15026791
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate 50 mg
Study: 9820262
Drug: Active hydroxycitric
Normalized name: hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active hydroxycitric acid (1500 mg per day)
Study: 7697476
Drug: Other nonsteroidal
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other nonsteroidal antiinflammatory drugs (aspirin, salsalate, salicylamide, lysine acetylsalicylate, acetaminophen, dipyrone, propyfenazone)
Study: 105164
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous insulin infusion
Study: 105164
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous bolus insulin
Study: 26362541
Drug: Topical medication
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medication (ocular hypotensive therapy)
Study: 23237583
Drug: Intrapregnancy non‐surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapregnancy non‐surgical periodontal treatment
Study: 23237583
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (deferred treatment until after delivery)
Study: 20945744
Drug: Combination bleaching
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination bleaching with 38% and 9.5% hydrogen peroxide gels (G II)
Study: 20945744
Drug: No bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bleaching (G I)
Study: 20945744
Drug: Combination bleaching
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination bleaching with sodium ascorbate (G IV)
Study: 20945744
Drug: Bleaching similar
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching similar to G II and restored after one week (G III)
Study: 8638454
Drug: 75g oral
Normalized name: Mesalamine 0.375g Oral capsule, biphasic release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75g oral glucose tolerance test (OGTT) performed first
Study: 8638454
Drug: 50g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50g oral glucose tolerance test (OGTT)
Study: 1993488
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole 3 days a week
Study: 30901344
Drug: Oral rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral rifampicin and trimethoprim/sulfamethoxazole for 21 days (arm A)
Study: 29972753
Drug: Patisiran (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran (0.3 mg/kg IV every 3 weeks)
Study: 24268548
Drug: Cocaine use
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine use during treatment
Study: 17609909
Drug: Baoshen Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baoshen Mixture (BSM) given orally thrice a day, 150 mL every time for 15 successive days
Study: 12577352
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Control group)
Study: 17609909
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received one cycle of chemotherapy program of 28‐30 days with conventional hydratization, alkalization and chloridization
Study: 17378193
Drug: Mild moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild moxibustion combined with cupping therapy
Study: 15622367
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) 1 g with normal saline before and after angiography
Study: 15622367
Drug: NAC (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC (i.v. at 1 g)
Study: 10874267
Drug: Intravenous RPR
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous RPR 109891
Study: 10874267
Drug: Oral RPR
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral RPR 109891
Study: 10874267
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus oral RPR 109891
Study: 19155764
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (including cilostazol)
Study: 17704423
Drug: mFU/LV (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFU/LV (monthly regimen)
Study: 11230476
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Study: 11230476
Drug: Six courses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Study: 9746385
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg (n = 218)
Study: 9746385
Drug: E2/NETA (17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (17beta‐oestradiol 2 mg plus norethisterone acetate 1 mg) (n = 219)
Study: 2894492
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 500 and 2000 micrograms thrice in 1 day
Study: 2894492
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 750 micrograms thrice daily for 14 days
Study: 30788847
Drug: Ticagrelor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (60 mg twice daily, reduced from 90 mg twice daily)
Study: 30788847
Drug: Placebo (on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (on top of low dose aspirin)
Study: 25639879
Drug: Submicron indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submicron indomethacin 40 mg
Study: 25639879
Drug: Submicron indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submicron indomethacin 20 mg
Study: 22384544
Drug: Xuezhikang (XZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (XZK) at a daily dose of 1.2 g, twice daily (large dose group)
Study: 22384544
Drug: Xuezhikang (XZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (XZK) at a daily dose of 0.6 g, twice daily (normal dose group)
Study: 22384544
Drug: Xuezhikang (XZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (XZK) (both doses)
Study: 16721690
Drug: IV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and III L pit SAs
Study: 10601068
Drug: Somatostatin plus
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin plus isosorbide 5-mononitrate (250 microg/hour + 40 mg/12 hours)
Study: 1313860
Drug: eight‐drugs‐in‐one‐day
Approvals — FDA: no, EMA: no, PMDA: no
Description: eight‐drugs‐in‐one‐day
Study: 2427983
Drug: Chemotherapy (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (4 courses + 20 Gy EF)
Study: 2427983
Drug: 6 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses chemotherapy + 20 Gy IF
Study: 2427983
Drug: Consolidation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation therapy 20 Gy IF
Study: 2427983
Drug: 2 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 courses chemotherapy
Study: 30055903
Drug: Apomorphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine infusion (mean final dose 4·68 mg/h)
Study: 25047762
Drug: A combination
Normalized name: Enema combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of nuclear β-catenin and atypical scores
Study: 10972367
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and beta-blockers
Study: 10558453
Drug: Nitrendipine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (in combination with other antihypertensive drugs)
Study: 7181807
Drug: Transdermal therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapeutic system‐scopolamine (1.0 mg over 3 days)
Study: 7181807
Drug: Transdermal therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapeutic system‐scopolamine (second treatment regimen)
Study: 7181807
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four treatments)
Study: 25337966
Drug: Adductor Canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor Canal (AC) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Study: 25337966
Drug: Peri-saphenous branch
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-saphenous branch of the descending genicular artery (Peri-SBDGA) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Study: 23810152
Drug: Pasteurized raw
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasteurized raw whole egg powder (1 teaspoon daily from 4 to 8 months)
Study: 23810152
Drug: Rice powder
Normalized name: White rice powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice powder (1 teaspoon daily from 4 to 8 months)
Study: 21675058
Drug: Daily Sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Sedative Interruption (DSI)
Study: 8015504
Drug: dl-norgestrel alone
Normalized name: Norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-norgestrel alone (0.075 mg/day) continuously for two cycles
Study: 8015504
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (dl-norgestrel and estradiol-17 beta) for six cycles
Study: 8015504
Drug: dl-norgestrel alone
Normalized name: Norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-norgestrel alone (0.075 mg/day) for two cycles
Study: 2597712
Drug: Behavioral Stepped-Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Stepped-Care treatment program (systolic feedback)
Study: 2597712
Drug: Behavioral Stepped-Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Stepped-Care treatment program (relaxation)
Study: 53554
Drug: Cimetidine 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1.6 g/day
Study: 29345724
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training (12-week program, twice a week for 45 minutes)
Study: 27698953
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1.14 g/day)
Study: 17140647
Drug: Fluticasone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone monotherapy
Study: 17140647
Drug: PACT combination
Normalized name: Poly Pact
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACT combination
Study: 14557438
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (1 mg every 12 h)
Study: 14557438
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (200 micro g/d)
Study: 14557438
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 micro g/d)
Study: 8984849
Drug: Risperidone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (various doses)
Study: 1311964
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral dose of dl-fenfluramine
Study: 2992724
Drug: Five-drug combination
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug combination (vincristine, doxorubicin, cisplatin, etoposide, cyclophosphamide)
Study: 25588320
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam microdose (0.001 mg)
Study: 25588320
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam regular dose (1 mg)
Study: 25588320
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam microdose (0.003 mg)
Study: 25588320
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam regular dose (3 mg)
Study: 23551803
Drug: Calcitonin nasal
Normalized name: calcitonin nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin nasal spray 200 IU
Study: 23551803
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) spray
Study: 19738321
Drug: L-DOPA 100
Normalized name: L-DOPA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA 100 mg daily for 5 weeks
Study: 11230723
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment for ICU anemia
Study: 9204224
Drug: Self-administered food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered food frequency questionnaire (FFQ)
Study: 8271800
Drug: Behavioral marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral marital therapy (BMT) alone
Study: 10718774
Drug: Solution
Normalized name: Solution
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution
Study: 21275549
Drug: Alendronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (35 mg/week)
Study: 21275549
Drug: Control (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Vitamin D, alfacalcidol 1 μg/day)
Study: 19074924
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in QRS duration over 60 min after fibrinolytic therapy
Study: 17276969
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg daily for 12 weeks
Study: 14975462
Drug: Reduced-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose tenecteplase (0.27 microg/kg) plus high-dose eptifibatide (2 boluses of 180 microg/kg separated by 10 min, 2.0 microg/kg/min infusion)
Study: 14975462
Drug: Reduced-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose tenecteplase plus high-dose eptifibatide
Study: 11532409
Drug: SPI experience
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI experience discussing rectal cancer
Study: 9541083
Drug: Operant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operant treatment alone
Study: 9541083
Drug: Common individual
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common individual rehabilitation therapy
Study: 2853934
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 50 mg three times daily
Study: 2853934
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 100 mg three times daily
Study: 2853934
Drug: Depot GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depot GnRH agonist alone
Study: 25458542
Drug: PiMg (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: PiMg (sodium picosulfate and magnesium citrate 500 mL plus 2L of clear fluids)
Study: 16396766
Drug: Topotecan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.25 mg/m² on days 1-5 for three 21-day cycles, followed by thalidomide starting at 100 mg/day (escalated to 300 mg/day if tolerated) for up to 1 year.
Study: 16396766
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg/day, escalated to 300 mg/day if tolerated) for up to 1 year.
Study: 12755459
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment plus contingency management (DT+)
Study: 12755459
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment (DT)
Study: 31765805
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of QLV and RV-LV
Study: 21679268
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life (QOL) assessment among treatment seeking MA users
Study: 19365295
Drug: Prescription copayment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription copayment (copay) policy
Study: 17020440
Drug: Overall frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall frequency of hospitalisation, emergency treatment, use of medication, detoxification
Study: 15496647
Drug: Oxcarbazepine 5
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine 5 mg/kg
Study: 15496647
Drug: Oxcarbazepine 15
Normalized name: oxcarbazepine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 15 mg/kg
Study: 15496647
Drug: Oxcarbazepine doses
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine doses of 11 to 68 mg/kg/day
Study: 24330605
Drug: RP-G28 (galacto-oligosaccharide)
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP-G28 (galacto-oligosaccharide) administered for 35 days
Study: 20542888
Drug: Intraoperative high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative high-dose remifentanil (0.25 microg kg(‐1) min(‐1))
Study: 20542888
Drug: Intraoperative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative low-dose remifentanil (0.1 microg kg(‐1) min(‐1))